Phase 2 Trial

A Phase 2 trial is the controlled efficacy-testing stage of drug development, run in patients who actually have the target disease or condition to determine whether the drug works well enough — and is safe enough in the short term — to justify the far larger commitment of a Phase 3 program. Under 21 CFR 312.21(b), Phase 2 “includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug.” That’s the pivot from Phase 1’s safety-and-dose focus to an explicit effectiveness question, though Phase 2 studies remain “well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.” See CASRAI’s Clinical Trial Phases guide for the full FDA phase sequence.

Phase 2a and Phase 2b: an industry convention, not a regulatory one

21 CFR 312.21 doesn’t subdivide Phase 2, but sponsors and CROs routinely do, informally, into two stages. Phase 2a is typically a smaller, shorter pilot study — sometimes called a proof-of-concept trial — aimed at establishing whether the drug shows a detectable efficacy signal and at refining dose selection. Phase 2b is a larger, better-controlled, dose-ranging or dose-confirming study designed to nail down the dose (or doses) that will be carried into Phase 3 and to generate a more statistically defensible efficacy estimate. Neither designation appears in FDA regulation; both are simply Phase 2 for regulatory purposes, filed under the same IND.

Control design and endpoints

Because Phase 2 is where an efficacy signal is first tested formally, control-group design matters more here than in Phase 1: most Phase 2 trials randomize participants to the investigational drug, a placebo, and/or an active comparator, and use blinding wherever feasible to limit bias in efficacy assessment. Primary endpoints shift from Phase 1’s pharmacokinetic and tolerability measures toward efficacy measures — often a validated surrogate or intermediate clinical endpoint rather than the hard clinical outcome (survival, irreversible morbidity) a confirmatory Phase 3 trial would use, since Phase 2 is sized to detect a signal, not to definitively establish benefit-risk.

Size, duration, and what happens next

FDA’s patient-facing guidance describes Phase 2 as typically involving up to several hundred participants with the disease or condition under study, running from several months to about two years. Historically, roughly a third of drugs entering Phase 2 advance to Phase 3 — the attrition reflects that Phase 2 is, by design, the stage where a lack of efficacy or an unacceptable short-term safety/efficacy trade-off is most likely to be discovered before the larger financial and participant-exposure commitment of Phase 3.

Administrative and regulatory context

Phase 2 trials remain governed by the same IND that covered Phase 1, and by the same safety-reporting obligations under 21 CFR 312.32 (7-calendar-day reporting for unexpected fatal/life-threatening suspected adverse reactions, 15 calendar days for other serious unexpected ones). Sponsors may request an end-of-Phase-2 meeting with FDA specifically to align on Phase 3 trial design before committing to it. See CASRAI’s Clinical Trial Phases guide for how Phase 2 fits alongside Phase 0, Phase 1, Phase 3, and Phase 4.